Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike.
Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike.
复制标题
DOI:
10.1016/j.isci.2021.103589
复制
发表时间:
2022-01-21
期刊:
影响因子:
5.8
通讯作者:
Whittaker GR
中科院分区:
文献类型:
--
作者:
Lubinski B;Fernandes MHV;Frazier L;Tang T;Daniel S;Diel DG;Jaimes JA;Whittaker GR
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent causing the COVID-19 pandemic. SARS-CoV-2 B.1.1.7 (Alpha), a WHO variant of concern first identified in the United Kingdom in late 2020, contains several mutations including P681H in the spike S1/S2 cleavage site, which is predicted to increase cleavage by furin, potentially impacting the viral cell entry. Here, we studied the role of the P681H mutation in B.1.1.7 cell entry. We performed assays using fluorogenic peptides mimicking the Wuhan-Hu-1 and B.1.1.7 S1/S2 sequence and observed no significant difference in furin cleavage. Functional assays using pseudoparticles harboring SARS-CoV-2 spikes and cell-to-cell fusion assays demonstrated no differences between Wuhan-Hu-1, B.1.1.7, or a P681H point mutant. Likewise, we observed no differences in viral growth between USA-WA1/2020 and a B.1.1.7 isolate in cell culture. Our findings suggest that, although the B.1.1.7 P681H mutation may slightly increase S1/S2 cleavage, this does not significantly impact viral entry or cell-cell spread. SARS-CoV-2 B.1.1.7 P681H mutation in the spike is predicted to enhance viral infection P681H does not significantly impact furin cleavage, viral entry, or cell-cell spread Other mutations in the SARS-CoV-2 B.1.1.7 VOC may account for increased infection rates Virology
登录
查看更多内容
DOI:
10.1126/science.abg3055
发表时间:
2021-04-09
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者:
Edmunds WJ
影响因子:
168.9
作者:
Chan, Jasper Fuk-Woo;Yuan, Shuofeng;Yuen, Kwok-Yung
通讯作者:
Yuen, Kwok-Yung
影响因子:
13.2
作者:
Jin, Xi;Xu, Kangli;Yang, Yida
通讯作者:
Yang, Yida
影响因子:
16.6
作者:
Dudas G;Hong SL;Potter BI;Calvignac-Spencer S;Niatou-Singa FS;Tombolomako TB;Fuh-Neba T;Vickos U;Ulrich M;Leendertz FH;Khan K;Huber C;Watts A;Olendraitė I;Snijder J;Wijnant KN;Bonvin AMJJ;Martres P;Behillil S;Ayouba A;Maidadi MF;Djomsi DM;Godwe C;Butel C;Šimaitis A;Gabrielaitė M;Katėnaitė M;Norvilas R;Raugaitė L;Koyaweda GW;Kandou JK;Jonikas R;Nasvytienė I;Žemeckienė Ž;Gečys D;Tamušauskaitė K;Norkienė M;Vasiliūnaitė E;Žiogienė D;Timinskas A;Šukys M;Šarauskas M;Alzbutas G;Aziza AA;Lusamaki EK;Cigolo JM;Mawete FM;Lofiko EL;Kingebeni PM;Tamfum JM;Belizaire MRD;Essomba RG;Assoumou MCO;Mboringong AB;Dieng AB;Juozapaitė D;Hosch S;Obama J;Ayekaba MO;Naumovas D;Pautienius A;Rafaï CD;Vitkauskienė A;Ugenskienė R;Gedvilaitė A;Čereškevičius D;Lesauskaitė V;Žemaitis L;Griškevičius L;Baele G
通讯作者:
Baele G
DOI:
10.1136/bmj.n579
发表时间:
2021-03-09
期刊:
BMJ (Clinical research ed.)
影响因子:
--
作者:
Challen R;Brooks-Pollock E;Read JM;Dyson L;Tsaneva-Atanasova K;Danon L
通讯作者:
Danon L